Prospective, Non Interventional Study to Evaluate the Safety Profile of First- Line Rituximab Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 May 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 03 Oct 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 03 Oct 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 27 Apr 2016 Time frame for primary endpoint chnaged from 4 years to 3 years.